Skip to content
value.today

Cassiopea SPA: peers

Change the peers

Cassiopea SPA beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

Cassiopea SPA, Atrys Health, S.A., Newron Pharmaceuticals, Genenta Science S.P.A.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

Cassiopea SPA, Atrys Health, S.A., Newron Pharmaceuticals, Genenta Science S.P.A., ARS Pharmaceuticals, Inc., Fennec Pharmaceuticals Inc., C4 Therapeutics, Inc., Nautilus Biotechnology, Inc. side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureCassiopea SPAbase
SKIN.SW · 🇮🇹 IT
Percentile in Healthcare
Percentile in Italy
Atrys Health, S.A.
ATRY.MC · 🇪🇸 ES
Percentile in Healthcare
Percentile in Spain
Newron Pharmaceuticals
NP5.F · 🇮🇹 IT
Percentile in Healthcare
Percentile in Italy
Genenta Science S.P.A.
GNTA · 🇮🇹 IT
Percentile in Healthcare
Percentile in Italy
ARS Pharmaceuticals, Inc.
SPRY · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Fennec Pharmaceuticals Inc.
FENC · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
C4 Therapeutics, Inc.
CCCC · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Nautilus Biotechnology, Inc.
NAUT · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Group median
Size
Market cap (Better neither way: ranked highest first)$380 Mlast known, Jan 7, 2022 · Market dataLast known value: no current one2nd of 8$312 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one6th of 8$190 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one7th of 8$63 MAug 1, 2026 · Market data8th of 8$375 MOct 28, 2026 · Market data3rd of 8$374 MOct 31, 2026 · Market data4th of 8$391 MOct 27, 2026 · Market data1st of 8$368 MOct 28, 2026 · Market data5th of 8$371 M8 ranked
Revenue (Better neither way: ranked highest first)——$159 MFY2025 · ESEF1st of 4————$84 MFY2025 · SEC2nd of 4$45 MFY2025 · SEC3rd of 4$36 MFY2025 · SEC4th of 4——$64 M4 ranked
Net income (Higher is better)——$-113 MFY2025 · ESEF5th of 6——$-7 MFY2025 · SEC1st of 6$-171 MFY2025 · SEC6th of 6$-10 MFY2025 · SEC2nd of 6$-105 MFY2025 · SEC4th of 6$-59 MFY2025 · SEC3rd of 6$-82 M6 ranked
Employees (Better neither way: ranked highest first)————————158December 31, 2025 · Profile1st of 435December 31, 2025 · Profile4th of 4121As on 2021 · Profile3rd of 4130December 31, 2025 · Profile2nd of 41264 ranked
Growth
Market cap change, 30 days (Higher is better)——————————-2.2%30 days to Oct 31, 2026 · Market data1st of 2-10.0%30 days to Oct 27, 2026 · Market data2nd of 2——-6.1%2 ranked
Revenue growth (Higher is better)————+13.0%FY2025 · ESEF1st of 456th68th————————-5.5%FY2025 · SEC3rd of 417th17th-6.1%FY2025 · SEC4th of 416th16th+1.0%FY2025 · SEC2nd of 428th32nd————-2.2%4 ranked
Revenue growth, 3 years a year (Higher is better)————————————————————+207.2%FY2025 · SEC1st of 299th100th+5.0%FY2025 · SEC2nd of 241st53rd————+106.1%2 ranked
Margins and returns
Operating margin (Higher is better)————-29.6%FY2025 · ESEF2nd of 438th6th————————-212.9%FY2025 · SEC3rd of 415th5th-14.1%FY2025 · SEC1st of 444th24th-320.5%FY2025 · SEC4th of 411th4th————-121.3%4 ranked
Net margin (Higher is better)————-71.1%FY2025 · ESEF2nd of 427th2nd————————-203.3%FY2025 · SEC3rd of 415th6th-21.8%FY2025 · SEC1st of 441st21st-292.0%FY2025 · SEC4th of 411th4th————-137.2%4 ranked
Free cash flow margin (Higher is better)————-5.7%FY2025 · ESEF1st of 344th23rd————————-203.1%FY2025 · SEC2nd of 315th5th————-276.2%FY2025 · SEC3rd of 313th3rd————-203.1%3 ranked
Return on equity (Higher is better)————-51.2%FY2025 · ESEF4th of 643rd3rd————-38.1%FY2025 · SEC2nd of 650th2nd-92.3%FY2025 · SEC6th of 627th11th-65.8%FY2025 · SEC5th of 635th15th-44.4%FY2025 · SEC3rd of 646th20th-32.3%FY2025 · SEC1st of 652nd23rd-47.8%6 ranked
Valuation
P/E ratio (Better neither way: ranked highest first)————————————————————185.1×price Oct 31, 2026 · Market dataonly one with it95th97th————————185.1×—
Price to sales (Better neither way: ranked highest first)————————————————3.1×price Oct 28, 2026 · Market data3rd of 344th61st5.6×price Oct 31, 2026 · Market data2nd of 360th79th12.1×price Oct 27, 2026 · Market data1st of 376th91st————5.6×3 ranked
Price to book (Better neither way: ranked highest first)————————————2.5×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price3.3×price Oct 28, 2026 · Market data2nd of 453rd65th10.5×price Oct 31, 2026 · Market data1st of 484th90th1.5×price Oct 27, 2026 · Market data4th of 431st37th2.4×price Oct 28, 2026 · Market data3rd of 441st53rd2.8×4 ranked
Free cash flow yield (Higher is better)————————————-12.3%price Aug 1, 2026 · Market datanot ranked: old priceold priceold price-45.7%price Oct 28, 2026 · Market data4th of 420th8th-0.6%price Oct 31, 2026 · Market data1st of 466th35th-25.4%price Oct 27, 2026 · Market data3rd of 429th13th-14.1%price Oct 28, 2026 · Market data2nd of 438th18th-19.8%4 ranked
Financial strength
Debt to equity (Lower is better)————————————————0.8×FY2025 · SEConly one with it71st62nd————————————0.8×—
Interest cover (Higher is better)————————————————————-3.0×FY2025 · SEConly one with it61st35th————————-3.0×—
Scorecard
Scorecard (Higher is better)——2 of 5FY2025 · Scorecard1st of 6——0 of 6FY2025 · Scorecard6th of 65 of 18FY2025 · Scorecard3rd of 68 of 20FY2025 · Scorecard1st of 64 of 21FY2025 · Scorecard5th of 63 of 12FY2025 · Scorecard4th of 626% passed6 ranked
Valuation checks (Higher is better)————————1 of 5FY2025 · Scorecard2nd of 41 of 5FY2025 · Scorecard2nd of 41 of 5FY2025 · Scorecard2nd of 41 of 4FY2025 · Scorecard1st of 420% passed4 ranked
Growth checks (Higher is better)——1 of 2FY2025 · Scorecard2nd of 6——0 of 2FY2025 · Scorecard4th of 60 of 3FY2025 · Scorecard4th of 63 of 5FY2025 · Scorecard1st of 61 of 5FY2025 · Scorecard3rd of 60 of 2FY2025 · Scorecard4th of 610% passed6 ranked
Profitability checks (Higher is better)——1 of 3FY2025 · Scorecard2nd of 6——0 of 2FY2025 · Scorecard5th of 61 of 5FY2025 · Scorecard3rd of 62 of 5FY2025 · Scorecard1st of 61 of 5FY2025 · Scorecard3rd of 60 of 3FY2025 · Scorecard5th of 620% passed6 ranked
Financial health checks (Higher is better)——————0 of 1FY2025 · Scorecard5th of 52 of 4FY2025 · Scorecard1st of 52 of 4FY2025 · Scorecard1st of 51 of 3FY2025 · Scorecard4th of 51 of 2FY2025 · Scorecard1st of 550% passed5 ranked
Shareholder returns checks (Higher is better)——————0 of 1FY2025 · Scorecard3rd of 51 of 1FY2025 · Scorecard1st of 50 of 1FY2025 · Scorecard3rd of 50 of 3FY2025 · Scorecard3rd of 51 of 1FY2025 · Scorecard1st of 50% passed5 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)——————1.7%2026-Q2 · 13F5th of 588.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 550.9%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 5104.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 533.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 550.9%5 ranked
Institutions holding (Better neither way: ranked highest first)——————92026-Q2 · 13F5th of 51892026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 51192026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 51522026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 5872026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 51195 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)————————-2.8 pp2026-Q2 against 2026-Q1 · 13F3rd of 4-0.5 pp2026-Q2 against 2026-Q1 · 13F2nd of 4+18.8 pp2026-Q2 against 2026-Q1 · 13F1st of 4-3.4 pp2026-Q2 against 2026-Q1 · 13F4th of 4-1.6 pp4 ranked
Dividends
Shareholder yield (Higher is better)————————————————————————0.1%FY2025 · SEConly one with it15th7th————0.1%—

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.

Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Cassiopea SPA: How market caps are worked out; Atrys Health, S.A.: How market caps are worked out; Newron Pharmaceuticals: How market caps are worked out; Genenta Science S.P.A.: How market caps are worked out; ARS Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Fennec Pharmaceuticals Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; C4 Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Nautilus Biotechnology, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
Cassiopea SPA———
Atrys Health, S.A.-29.6%FY2025
38th percentile in Healthcaremedian -7.7%, 674 companies
6th percentile in Spainmedian 9.2%, 79 companies
Newron Pharmaceuticals———
Genenta Science S.P.A.———
ARS Pharmaceuticals, Inc.-212.9%FY2025
15th percentile in Healthcaremedian -7.7%, 674 companies
5th percentile in USAmedian 3.5%, 2,594 companies
Fennec Pharmaceuticals Inc.-14.1%FY2025
44th percentile in Healthcaremedian -7.7%, 674 companies
24th percentile in USAmedian 3.5%, 2,594 companies
C4 Therapeutics, Inc.-320.5%FY2025
11th percentile in Healthcaremedian -7.7%, 674 companies
4th percentile in USAmedian 3.5%, 2,594 companies
Nautilus Biotechnology, Inc.———

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$40 M$79 M$119 M$159 M20212022202320242025Atrys Health, S.A. $159 MARS Pharmaceuticals, Inc. $84 MFennec Pharmaceuticals Inc. $45 MC4 Therapeutics, Inc. $36 M

Rank in the group

1st2nd3rd4th20212022202320242025Atrys Health, S.A.: 1st of 4 in 2024Atrys Health, S.A.: 1st of 4 in 2025Atrys Health, S.A.ARS Pharmaceuticals, Inc.: 2nd of 2 in 2021ARS Pharmaceuticals, Inc.: 3rd of 3 in 2022ARS Pharmaceuticals, Inc.: 3rd of 3 in 2023ARS Pharmaceuticals, Inc.: 2nd of 4 in 2024ARS Pharmaceuticals, Inc.: 2nd of 4 in 2025ARS Pharmaceuticals, Inc.Fennec Pharmaceuticals Inc.: 2nd of 3 in 2022Fennec Pharmaceuticals Inc.: 1st of 3 in 2023Fennec Pharmaceuticals Inc.: 3rd of 4 in 2024Fennec Pharmaceuticals Inc.: 3rd of 4 in 2025Fennec Pharmaceuticals IncC4 Therapeutics, Inc.: 1st of 2 in 2021C4 Therapeutics, Inc.: 1st of 3 in 2022C4 Therapeutics, Inc.: 2nd of 3 in 2023C4 Therapeutics, Inc.: 4th of 4 in 2024C4 Therapeutics, Inc.: 4th of 4 in 2025C4 Therapeutics, Inc.
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearCassiopea SPAAtrys Health, S.A.Newron PharmaceuticalsGenenta Science S.P.A.ARS Pharmaceuticals, Inc.Fennec Pharmaceuticals Inc.C4 Therapeutics, Inc.Nautilus Biotechnology, Inc.
2025—$159 MESEF1st——$84 MSEC2nd$45 MSEC3rd$36 MSEC4th—
2024—$141 MESEF1st——$89 MSEC2nd$48 MSEC3rd$36 MSEC4th—
2023————$0 MSEC3rd$21 MSEC1st$21 MSEC2nd—
2022————$1 MSEC3rd$2 MSEC2nd$31 MSEC1st—
2021————$6 MSEC2nd—$46 MSEC1st—
2020—————$0 MSEC——

Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of Cassiopea SPA#

Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • Atrys Health, S.A.ATRY.MC · 🇪🇸 Spain
    Same industry: Biotechnology · Similar size: $312 M market cap against $380 M · Same region: Southern Europe · Ratios of the last two fiscal years on file
    Market cap $312 M (last known, Jan 5, 2024) · revenue $159 M (year to December 2025)
    91 of 100 (industry or sector 50 + size 29 + country 7 + figures on file 5)
    In the group
  • Newron PharmaceuticalsNP5.F · 🇮🇹 Italy
    Same industry: Biotechnology · Similar size: $190 M market cap against $380 M · Same country: Italy
    Market cap $190 M (last known, Jan 5, 2024)
    90 of 100 (industry or sector 50 + size 26 + country 15)
    In the group
  • Genenta Science S.P.A.GNTA · 🇮🇹 Italy
    Same industry: Biotechnology · 6.0× smaller by market cap · Same country: Italy · Ratios of the last two fiscal years on file
    Market cap $63 M (Aug 1, 2026)
    88 of 100 (industry or sector 50 + size 18 + country 15 + figures on file 5)
    In the group
  • ARS Pharmaceuticals, Inc.SPRY · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $375 M market cap against $380 M · Ratios of the last two fiscal years on file
    Market cap $375 M (Oct 28, 2026) · revenue $84 M (year to December 2025)
    85 of 100 (industry or sector 50 + size 30 + figures on file 5)
    In the group
  • Fennec Pharmaceuticals Inc.FENC · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $374 M market cap against $380 M · Ratios of the last two fiscal years on file
    Market cap $374 M (Oct 31, 2026) · revenue $45 M (year to December 2025)
    85 of 100 (industry or sector 50 + size 30 + figures on file 5)
    In the group
  • C4 Therapeutics, Inc.CCCC · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $391 M market cap against $380 M · Ratios of the last two fiscal years on file
    Market cap $391 M (Oct 27, 2026) · revenue $36 M (year to December 2025)
    85 of 100 (industry or sector 50 + size 30 + figures on file 5)
    In the group
  • Nautilus Biotechnology, Inc.NAUT · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $368 M market cap against $380 M · Ratios of the last two fiscal years on file
    Market cap $368 M (Oct 28, 2026)
    85 of 100 (industry or sector 50 + size 30 + figures on file 5)
    In the group
  • Rezolute, Inc.RZLT · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $398 M market cap against $380 M · Ratios of the last two fiscal years on file
    Market cap $398 M (Oct 28, 2026)
    85 of 100 (industry or sector 50 + size 30 + figures on file 5)
    + Add
  • Opus Genetics, Inc.IRD · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $396 M market cap against $380 M · Ratios of the last two fiscal years on file
    Market cap $396 M (Oct 15, 2026) · revenue $14 M (year to December 2025)
    85 of 100 (industry or sector 50 + size 30 + figures on file 5)
    + Add
  • Nanobiotix S.A.NANO.PA · 🇫🇷 France
    Same industry: Biotechnology · Similar size: $363 M market cap against $380 M · Ratios of the last two fiscal years on file
    Market cap $363 M (last known, Jan 5, 2024) · revenue $33 M (year to December 2025)
    85 of 100 (industry or sector 50 + size 30 + figures on file 5)
    + Add
  • Editas Medicine, Inc.EDIT · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $363 M market cap against $380 M · Ratios of the last two fiscal years on file
    Market cap $363 M (Oct 19, 2026) · revenue $41 M (year to December 2025)
    85 of 100 (industry or sector 50 + size 30 + figures on file 5)
    + Add
  • Hyloris Pharmaceuticals SAHYL.BR · 🇧🇪 Belgium
    Same industry: Biotechnology · Similar size: $404 M market cap against $380 M · Ratios of the last two fiscal years on file
    Market cap $404 M (last known, Jan 5, 2024) · revenue $8 M (year to December 2025)
    85 of 100 (industry or sector 50 + size 30 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.